Wave Life Sciences Ltd. — Director's Dealing 2017

Sep 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2017-09-15

Reporting Person: Tanaka Masaharu (Director, 10% Owner)
Reporting Person: Kagoshima Shinsangyo Sousei Investment Limited Partnership (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-15	Ordinary Shares	S	14385	$24.22	Disposed	2780480	Indirect
2017-09-18	Ordinary Shares	S	6362	$24.19	Disposed	2774118	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.

F3: (Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.